Description

Global Relapsed and Refractory Multiple Myeloma Treatment Market

Market Outline: 

Relapsed multiple myeloma occurs when the multiple myeloma disease or its signs and symptoms return after a period of improvement. Relapsed and Refractory Multiple Myeloma Treatment Market occurs when the disease in unresponsive to a primary therapy or it becomes unresponsive over time. Multiple myeloma or plasma cell myeloma, is a cancer of plasma cells, a type of WBC normally responsible for the production of antibodies. At initial stage, there are no symptoms noticed with multiple myeloma, however, in advanced stage bleeding, bone pain, anemia, and frequent infections may occur. Risk factors for multiple myeloma are high consumption of alcohol and obesity. It may causes due to abnormal production of antibodies may cause renal problems and increase in the thickness of blood. The disease can be considered as treatable, but incurable. It can be treated with radiotherapy, chemotherapy, and stem cell transplantation among others.

Market Dynamics:

Increase in the prevalence of relapsed and refractory multiple myeloma, rise in R&D for the innovation of newer drugs, funding for the R&D activities from public and private sectors, and promising pipeline products are anticipated to fuel the relapsed and refractory multiple myeloma treatment market over the forecast years. Moreover, increase in awareness about relapsed and refractory myeloma treatment, government initiations for prevention of cancer, and launching of newer products into the market are bolster the relapsed and refractory multiple myeloma treatment market. However, stringent regulatory policies for product approval, high cost of R&D activities, and adverse effects associated with chemotherapy and radiotherapy may hinder the growth of the market over the forecast timeframe.

Market Scope:

Global Relapsed and refractory multiple myeloma treatment market is segmented on the basis of treatment type, drug class, route of administration, distribution channel, and region

Based on the treatment type, the market is segmented into the following:

  • Chemotherapy
  • Radiotherapy
  • Stem Cell Transplantation
  • Others

Based on drug class, the market is segmented into the following:

  • Monoclonal Antibodies
  • Immunomodulatory Drugs
  • Proteasome Inhibitors
  • Steroids
  • Others

Based on route of administration, the market is segmented into the following:

  • Oral
  • Parenteral

Based on the distribution channel, the market is segmented into the following:

  • Hospitals
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on region, the market is segmented into the following:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Market Summary:

Global relapsed and refracted multiple myeloma market is poised to grow at a significant CAGR owing to increase in the prevalence of multiple myeloma. According to World Cancer Research Fund International 2012, approximately 114,000 multiple myeloma cases observed around the world. According to Novartis data 2015, approximately 75,000 people are living with relapsed and refractory multiple myeloma around the globe. Moreover, strong product pipeline for relapsed and refractory multiple myeloma treatment expected to boost the market. For instance, in April 2017, Genmab A/S announced that Janssen Research and Development LLC collaborated with European Myeloma Network (EMN) to start phase III study of daratumumab in combination with dexamethasone and pomalidomide in relapsed and refractory multiple myeloma. In addition, FDA approval for various drugs might upsurge the revenue of market. For instance, in January 2016, Amgen received FDA approval for supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) injection in combination with lenalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma.

Regional Analysis:

Geographically, relapsed and refractory multiple myeloma treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America relapsed and refractory multiple myeloma treatment market driven by rise in prevalence of multiple myeloma disease and FDA product approval. Europe relapsed and refractory multiple myeloma treatment market exhibiting lucrative growth owing to adoption of newer drugs, sophisticated healthcare infrastructure, and rise in prevalence of multiple myeloma in the region. Asia Pacific relapsed and refractory multiple myeloma treatment market is driven by government initiations for the prevention of cancer, rise in disposable income, and increase in R&D for innovation of newer drugs are fuel the market.

Major Key Players:

  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca plc (U.K.)
  • Novartis AG (Switzerland)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GenMab A/S (Denmark)
  • Amgen Inc. (U.S.)
  • Janssen Pharmaceuticals, Inc. (Johnson & Johnson Services, Inc.) (U.S.)
  • Unum Therapeutics (U.S.)
  • Bristol-Myers Squibb (U.S.)
  • Celgene Corporation (U.S.)
  • Bluebird Bio, Inc. (U.S.)

Notable Market Developments: 

  • In November 2017, Celgene corporation and bluebird bio received a breakthrough therapy designation from FDA and prime eligibility from EMA for bb2121 Anti-BCMA Car-T cell therapy for the treatment of relapsed and refractory multiple myeloma
  • In August 2017, Unum Therapeutics announced investigational new drug (IND) application for ACTR087 in combination with SEA-BCMA for the treatment of relapsed and refractory multiple myeloma

Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2019) and forecast (2020 to 2026)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market


Location

GEOGRAPHY

PBI Location Map

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX